Clinical Trials Browser

Esophageal Neoplasms

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms

Neuroendocrine Tumors

Squamous Cell Carcinoma of Head and Neck

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma

Carcinoma, Non-Small-Cell Lung

Lung Neoplasms

Adenocarcinoma Of Esophagus, Esophageal Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Carcinoma, Non-Small-Cell Lung

Parkinson Disease 4, Autosomal Dominant Lewy Body

Carcinoma, Non-Small-Cell Lung

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Cervical Neoplasms

Carcinoma, Non-Small-Cell Lung

Endometrial Neoplasms

Small Cell Lung Carcinoma

Medulloblastoma

Mesothelioma, Malignant

Non-Small-Cell Lung

Squamous Cell Carcinoma of Head and Neck

Mesothelioma, Malignant, Mesothelioma

Glioblastoma

Glioblastoma

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

Uterine Cervical Neoplasms

Breast Neoplasms

Ovarian Neoplasms

Clinical Trials

PROTECT

Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery

Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer

Randomized Phase II Study of DCE-MRI-based Dose Escalation for Poor-prognosis and Neck Cancer

HIPEC

Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)

KEYLYNK-008

Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)

AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer

Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer

Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer

Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer

LEAP-006

MK-7684A-007

KEYNOTE-826

SKYSCRAPER-06

LEAP-001

SKYSCRAPER-02

Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma

CheckMate 6DW

A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)

Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck Cancer

DREAM3R

Exablate Blood-Brain Barrier Disruption for the Treatment of rGBM in Subjects Undergoing Carboplatin Monotherapy

Exablate Blood-Brain Barrier Disruption With Carboplatin for the Treatment of rGBM

A Study Describing Real-World Effectiveness of Nivolumab + Chemotherapy in Neoadjuvant NSCLC

CheckMate 816

Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors

Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy

Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease

EWOC-1